Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test whether Fondaparinux is effective and safe to prevent thromboembolic events (like for example strokes) and bleeding events in patients who undergo a normalisation of their heart rhythm disturbance. Fondaparinux will be compared with Heparin and tablets containing Vitamin-K-Antagonists (Phenprocoumon, Fluindione, or Warfarin).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00911300
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date August 2009
Completion date September 2011

See also
  Status Clinical Trial Phase
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Terminated NCT00437242 - Odiparcil QT Definitive Study Phase 1
Completed NCT00402363 - Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation Phase 3
Completed NCT00240643 - Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke Phase 2
Completed NCT00041496 - Prevention Of Recurrence Of Atrial Fibrillation Phase 2
Withdrawn NCT03401931 - Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers
Completed NCT04537507 - Atrial Fibrillation and Non-obstructive Coronary Lesions
Completed NCT04761315 - Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)
Not yet recruiting NCT06200311 - Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men N/A